Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (1064)	8/6/1998 8:39:00 PM
From: Bob Swift	Respond to of 10280

SEPR 2nd quarter loss, if anyone cares, 63 cents versus 56 cents. I was actually expecting a lot more since they(we) are supposedly building up a sales force. Does anyone know who is going to manufacture the ICE ? Is it Chirex ?

To: Ed Ajootian who wrote (1064)	8/6/1998 9:27:00 PM
From: David Howe	Read Replies (3) \| Respond to of 10280

Ed, I'm sorry but I just don't agree. SEPR is far beyond the development stage. Levalbuterol is approved. The sales force is ready to go. Major products, patents, developments, and partnerships are announced every few weeks. The FDA will fast track each of SEPR's products. The risk of product failure that is common with biotech companies just doesn't exist with SEPR. Huge profits are just around the corner. Earnings estimates of $5 - 8 per share in 2001 are very conservative. Big Pharmas are partnering with SEPR left and right. Can anyone say Prozac? How about cornering the entire antihistamine market? Products that are better than the original; safer, fewer side effects, faster acting. The FDA actually requiring the original product to be pulled from the shelf once SEPR's is approved. Once SEPR gets a couple of products to market and the earnings start rolling in they will use them to finance product sales on their own increasing margins considerably. You can forget 10 - 15% royalties - bring on 60 - 70% gross margin. Try those numbers on for size with a drug in the $1 billion market range (how many of these does SEPR have?) - you'll find it slightly encouraging. This will happen about the same time that SEPR hits the market with a large part of their pipeline. Earnings will increase exponentially. The market share that SEPR can take from Lilly, J&J, Merck, etc. etc. has them all shaking in their boots. A takeover attempt is very likely and you can bet it will be a serious bidding war. No pharma is going to want one of it's competitors to suddenly have SEPR's portfolio all to themselves. $50 per share is an absolute bargain. I love market corrections! I'm not even going to hint at what I think a share of SEPR will go for in 2002. You'd fall off your chair. Nobody will pay more than $50 a share? Soros did, I can guarantee it. Dave